Christine Mateus
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 68
- Cancer Immunotherapy and Biomarkers 48
- Cutaneous Melanoma Detection and Management 13
- CAR-T cell therapy research 11
- Colorectal Cancer Treatments and Studies 6
- HER2/EGFR in Cancer Research 5
- Immunology 14
- Immunotherapy and Immune Responses 5
- Co-authors
- Caroline Robert (52 shared papers)Émilie Routier (19 shared papers)Stephane Champiat (18 shared papers)Émilie Lanoy (10 shared papers)Franck Carbonnel (12 shared papers)Olivier Lambotte (18 shared papers)Aurélien Marabelle (15 shared papers)Jean‐Charles Soria (9 shared papers)
- Journals
- European Journal of Cancer (10 papers)Annals of Oncology (10 papers)Supportive Care in Cancer (3 papers)Cancer Research (3 papers)BMJ Supportive & Palliative Care (3 papers)
- Partner nations
- FranceUnited StatesCanada
In The Last Decade
Christine Mateus
96 papers receiving 25.5k citations
Christine Mateus's Hit Papers
Peers
Comparison fields: 5 of 136
- Oncology 18.5k
- Immunology 8.9k
- Genetics 1.0k
- Pulmonary and Respiratory Medicine 2.9k
- Cancer Research 1.1k
Countries citing papers authored by Christine Mateus
This map shows the geographic impact of Christine Mateus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine Mateus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine Mateus more than expected).
Fields of papers citing papers by Christine Mateus
This network shows the impact of papers produced by Christine Mateus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine Mateus. The network helps show where Christine Mateus may publish in the future.
Co-authors
The 25 scholars most cited alongside Christine Mateus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 103 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | PD-1 blockade induces responses by inhibiting adaptive immune resistance Hit paper breakdown → | 2014 | 5527 |
| 2 | Pembrolizumab versus Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2015 | 4893 |
| 3 | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Hit paper breakdown → | 2013 | 2928 |
| 4 | Immune-related adverse events with immune checkpoint blockade: a comprehensive review Hit paper breakdown → | 2016 | 1785 |
| 5 | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Hit paper breakdown → | 2014 | 1540 |
| 6 | Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab Hit paper breakdown → | 2017 | 1106 |
| 7 | Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination Hit paper breakdown → | 2016 | 910 |
| 8 | Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma Hit paper breakdown → | 2016 | 905 |
| 9 | Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper Hit paper breakdown → | 2015 | 728 |
| 10 | Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab Hit paper breakdown → | 2015 | 564 |
| 11 | Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors Hit paper breakdown → | 2018 | 446 |
| 12 | Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer Hit paper breakdown → | 2020 | 424 |
| 13 | 2013 | 416 | |
| 14 | 2016 | 283 | |
| 15 | 2018 | 247 | |
| 16 | 2018 | 229 | |
| 17 | 2017 | 166 | |
| 18 | 2009 | 150 | |
| 19 | 2014 | 145 | |
| 20 | 2015 | 143 |
About Christine Mateus
Christine Mateus is a scholar working on Oncology, Immunology, Dermatology, Molecular Biology and Pharmacology, having authored 103 papers that have together received 26.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (48 papers), Melanoma and MAPK Pathways (17 papers), Cutaneous Melanoma Detection and Management (13 papers), CAR-T cell therapy research (11 papers), Colorectal Cancer Treatments and Studies (6 papers), Drug-Induced Adverse Reactions (6 papers), HER2/EGFR in Cancer Research (5 papers) and Immunotherapy and Immune Responses (5 papers). The work is most often cited by research in Oncology (18.5k citations), Immunology (8.9k citations), Genetics (1.0k citations), Pulmonary and Respiratory Medicine (2.9k citations) and Cancer Research (1.1k citations). Christine Mateus has collaborated with scholars based in France, United States and Canada. Frequent co-authors include Caroline Robert, Émilie Routier, Stephane Champiat, Émilie Lanoy, Franck Carbonnel, Olivier Lambotte, Aurélien Marabelle, Jean‐Charles Soria, Alexander M.M. Eggermont and Nathalie Chaput. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Supportive Care in Cancer, Cancer Research and BMJ Supportive & Palliative Care.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.